You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProcyclidine
Accession NumberDB00387  (APRD00383)
TypeSmall Molecule
GroupsApproved
Description

A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. [PubChem]

Structure
Thumb
Synonyms
1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride
1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol
Prociclidina
Procyclidin
Procyclidine
Procyclidinum
Tricyclamol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Kemadrin Elxelixir2.5 mgoralGlaxosmithkline Inc1968-12-312004-08-05Canada
Kemadrin Tab 5mgtablet5 mgoralGlaxosmithkline Inc1956-12-312004-12-02Canada
Pdp-procyclidineelixir2.5 mgoralPendopharm Division Of De Pharmascience Inc1984-12-31Not applicableCanada
Pdp-procyclidinetablet2.5 mgoralPendopharm Division Of De Pharmascience Inc1985-12-31Not applicableCanada
Pdp-procyclidinetablet5 mgoralPendopharm Division Of De Pharmascience Inc1985-12-31Not applicableCanada
Pendo-procyclidinetablet2.5 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-procyclidine Tabletstablet5 mgoralPharmel Inc1998-02-172010-11-03Canada
PHL-procyclidine Tabletstablet2.5 mgoralPharmel Inc1998-02-172010-11-03Canada
Procyclid Elxelixir2.5 mgoralIcn Canada Ltd.1980-12-312005-04-26Canada
Procyclid Tab 5mgtablet5 mgoralIcn Canada Ltd.1974-12-312005-04-26Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArpicolinRosemont
ExtranilGeneral Pharma
KdrineOpsonin
KemadrenGlaxoSmithKline
KemadrinGlaxoSmithKline
OsnervanAspen
ProdinePsyco Remedies
ProimerCho Dang
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Procyclidine hydrochloride
ThumbNot applicableDBSALT001008
Categories
UNIIC6QE1Q1TKR
CAS number77-37-2
WeightAverage: 287.4397
Monoisotopic: 287.224914555
Chemical FormulaC19H29NO
InChI KeyInChIKey=WYDUSKDSKCASEF-UHFFFAOYSA-N
InChI
InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
IUPAC Name
1-cyclohexyl-1-phenyl-3-(pyrrolidin-1-yl)propan-1-ol
SMILES
OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Aralkylamine
  • N-alkylpyrrolidine
  • Tertiary alcohol
  • Pyrrolidine
  • 1,3-aminoalcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents.
PharmacodynamicsProcyclidine has an atropine-like action on parasympathetic-innervated peripheral structures including smooth muscle. It's antispasmodic effects are thought to be related to the blockage of central cholinergic receptors M1, M2 and M4. It is used to treat symptomatic Parkinsonism and extrapyramidal dysfunction caused by antipsychotic agents.
Mechanism of actionThe mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingApproximately 100% bound to albumin.
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=60 mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9822
Blood Brain Barrier+0.9734
Caco-2 permeable+0.6388
P-glycoprotein substrateSubstrate0.6324
P-glycoprotein inhibitor INon-inhibitor0.51
P-glycoprotein inhibitor IINon-inhibitor0.5877
Renal organic cation transporterInhibitor0.7954
CYP450 2C9 substrateNon-substrate0.7956
CYP450 2D6 substrateNon-substrate0.7907
CYP450 3A4 substrateNon-substrate0.5427
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.915
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.841
CarcinogenicityNon-carcinogens0.9142
BiodegradationNot ready biodegradable0.9178
Rat acute toxicity2.7861 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6498
hERG inhibition (predictor II)Inhibitor0.5597
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Monarch pharmaceuticals inc
PackagersNot Available
Dosage forms
FormRouteStrength
Elixiroral2.5 mg
Tabletoral2.5 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Pms-Procyclidine 2.5 mg Tablet0.06USD tablet
Pms-Procyclidine 0.5 mg/ml Elixir0.03USD ml
Pms-Procyclidine 5 mg Tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point86 °CPhysProp
water solubilityModerately soluble in water, ~ 30 mg/mlNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00984 mg/mLALOGPS
logP4.13ALOGPS
logP3.79ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.6 m3·mol-1ChemAxon
Polarizability34.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9010000000-7d7f1b16f54aaca37f10View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Theodoridis GC, Stark L: Central role of solar information flow in pregenetic evolution. J Theor Biol. 1971 Jun;31(3):377-88. [PubMed:5556140 ]
External Links
ATC CodesN04AA04
AHFS Codes
  • 12:08.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Procyclidine is combined with Acetylsalicylic acid.
AclidiniumAclidinium may increase the anticholinergic activities of Procyclidine.
AlfentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Alfentanil.
AmitriptylineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Amoxapine.
AtropineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atropine.
AzelastineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Azelastine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Procyclidine.
BenzatropineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Benzatropine.
Botulinum Toxin Type AProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrompheniramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Brompheniramine.
BuprenorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Butorphanol.
CaffeineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Caffeine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Carbinoxamine.
CetirizineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cetirizine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlordiazepoxide.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlorpromazine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Procyclidine.
Cimetropium BromideProcyclidine may increase the anticholinergic activities of Cimetropium Bromide.
CisaprideThe therapeutic efficacy of Cisapride can be decreased when used in combination with Procyclidine.
ClemastineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Clidinium.
ClofedanolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Clofedanol.
ClomipramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Clomipramine.
ClozapineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Clozapine.
CodeineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Codeine.
CyclizineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclopentolate.
CyproheptadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyproheptadine.
DarifenacinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin.
DesipramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desloratadine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dexbrompheniramine.
Dexchlorpheniramine maleateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dexchlorpheniramine maleate.
DicyclomineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.
DifenoxinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydrocodeine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenoxylate.
DisopyramideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Disopyramide.
DonepezilThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Donepezil.
DoxepinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Doxepin.
DoxylamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Doxylamine.
DronabinolProcyclidine may increase the tachycardic activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Droperidol.
EdrophoniumThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Edrophonium.
EluxadolineProcyclidine may increase the activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Procyclidine.
FenoterolFenoterol may increase the anticholinergic activities of Procyclidine.
FentanylThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl.
FesoterodineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.
FexofenadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fexofenadine.
FlavoxateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Flavoxate.
FlupentixolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fluphenazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fluticasone Propionate.
GalantamineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Glycopyrrolate.
HaloperidolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Haloperidol.
HomatropineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Homatropine.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procyclidine.
HydrocodoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.
HydroxyzineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hyoscyamine.
ImipramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Procyclidine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Procyclidine is combined with Isocarboxazid.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Procyclidine.
LevocetirizineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levocetirizine.
LevorphanolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levorphanol.
LoratadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Loratadine.
LoxapineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Loxapine.
MaprotilineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Meclizine.
MepenzolateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mepenzolate.
MethadoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methotrimeprazine.
MethscopolamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methscopolamine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Procyclidine.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Procyclidine.
MianserinMianserin may increase the anticholinergic activities of Procyclidine.
MirabegronThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mirabegron.
MoclobemideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Moclobemide.
MorphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.
NabiloneProcyclidine may increase the tachycardic activities of Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Procyclidine.
NalbuphineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Neostigmine.
NortriptylineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Olopatadine.
OrphenadrineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxymorphone.
PentazocineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.
PerphenazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Phenelzine.
PhysostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Physostigmine.
PimozideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pimozide.
PizotifenThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pizotifen.
Potassium ChlorideProcyclidine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Procyclidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Propantheline.
ProtriptylineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Protriptyline.
PyridostigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Pyridostigmine.
QuetiapineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Quetiapine.
RamosetronProcyclidine may increase the activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Remifentanil.
RisperidoneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Risperidone.
RivastigmineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.
SolifenacinThe risk or severity of adverse effects can be increased when Procyclidine is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.
TacrineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tapentadol.
ThioridazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Procyclidine is combined with Thiothixene.
TiotropiumProcyclidine may increase the anticholinergic activities of Tiotropium.
TolterodineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Procyclidine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tramadol.
TranylcypromineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tranylcypromine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Procyclidine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trifluoperazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trihexyphenidyl.
TrimethobenzamideThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimethobenzamide.
TrimipramineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Triprolidine.
TrospiumThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trospium.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Procyclidine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Procyclidine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Larson EW, Pfenning MA, Richelson E: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology (Berl). 1991;103(2):162-5. [PubMed:2027917 ]
  4. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Larson EW, Pfenning MA, Richelson E: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology (Berl). 1991;103(2):162-5. [PubMed:2027917 ]
  4. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Tacke R, Christophe J: Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol. 1990 Sep 18;189(2-3):135-42. [PubMed:2253700 ]
  4. Alberts P: Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. [PubMed:7616431 ]
  5. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  6. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. doi: 10.1016/j.neuro.2010.07.002. Epub 2010 Jul 17. [PubMed:20624420 ]
  2. Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. [PubMed:1426023 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23